Mendelian susceptibility to mycobacterial disease (MSMD) is a primary immunodeficiency syndrome characterized by severe disease caused by weakly virulent mycobacteria, such as BCG vaccines and environmental mycobacteria, in otherwise healthy patients. Patients with MSMD are also vulnerable to tuberculosis. Other infections are rare, with the exception of non-typhoidal salmonellosis, found in about half the patients. First described clinically in the 1950s, the pathogenesis of MSMD remained unclear until 1996, when its first genetic etiology was deciphered in children with interferon-3 receptor 1 (IFN-?R1) deficiency. Genetic dissection of MSMD over the last 15 years has identified six morbid genes, including five autosomal (IFNGR1, IFNGR2, STAT1, IL12B, IL12RB1) and one X-linked (NEMO) gene. The high level of allelic heterogeneity at these six loci has led to the definition of up to 13 distinct disorders, with dominant and recessive traits at the same locus, complete and partial defects of the same protein, and defects due to a lack of protein or the production of a dysfunctional protein. The pathogenesis of MSMD in patients with these disorders involves impaired interleukin-12 (IL-12)-dependent IFN-? immunity. However, only about half the 500 patients tested in our laboratory carried any of these genetic defects. We hypothesize that MSMD in other patients results from other monogenic inborn errors of immunity, possibly but not necessarily involving the IL- 12-IFN-? circuit. The principal objective of the work described in this application is therefore to identify new MSMD-causing genetic disorders, including new defects allelic with the known MSMD etiologies, and new MSMD-causing genes. We will use two complementary experimental approaches, a hypothesis-based candidate gene approach and a hypothesis-generating genome-wide screening approach. In the candidate gene approach, we will sequence selected candidate genes in the IL-12-IFN-? circuit. In the genome-wide screening approach, we will search for and characterize MSMD-causing genes by genome-wide linkage and deep sequencing. By sequencing candidate genes, we have already obtained preliminary evidence of at least three new MSMD-causing defects, with autosomal dominant forms of IFN-?R2, IL-12R?2 and IRF8 deficiency. By genome-wide linkage, we have also obtained preliminary evidence of three novel MSMD-causing genes, with recessive mutations in X-linked CYBB and autosomal TYK2 and JAK2. Our project is innovative, feasible, and supported by strong preliminary evidence. From a basic biological standpoint, this research will provide considerable insight into the mechanisms of immunity to mycobacteria. Elucidation of the molecular genetic basis of MSMD will also shed light on the pathogenesis of mycobacterial disease, making it possible to provide molecular diagnoses for patients and genetic counseling for families. This new information will pave the way for the use of IFN-? for treatment in addition to antibiotics. Finally, the genetic dissection of MSMD will pave the way for the genetic dissection of severe tuberculosis in otherwise healthy children.

Public Health Relevance

The known genetic etiologies of Mendelian susceptibility to mycobacterial disease (MSMD) impair interferon (IFN)-?-mediated immunity. Nearly half the patients with MSMD lack a genetic etiology. We hypothesize that MSMD in these patients also results from inborn errors of immunity, which we aim to identify by candidate gene and genome-wide approaches.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI089970-03
Application #
8305432
Study Section
Special Emphasis Panel (ZRG1-IMM-K (52))
Program Officer
Johnson, David R
Project Start
2010-07-01
Project End
2015-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
3
Fiscal Year
2012
Total Cost
$501,584
Indirect Cost
$204,789
Name
Rockefeller University
Department
Genetics
Type
Other Domestic Higher Education
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Esteve-Solé, Ana; Sologuren, Ithaisa; Martínez-Saavedra, María Teresa et al. (2018) Laboratory evaluation of the IFN-? circuit for the molecular diagnosis of Mendelian susceptibility to mycobacterial disease. Crit Rev Clin Lab Sci 55:184-204
Alodayani, Abdulrahman N; Al-Otaibi, Abdulnasir M; Deswarte, Caroline et al. (2018) Mendelian Susceptibility to Mycobacterial Disease Caused by a Novel Founder IL12B Mutation in Saudi Arabia. J Clin Immunol 38:278-282
Kong, Xiao-Fei; Martinez-Barricarte, Ruben; Kennedy, James et al. (2018) Disruption of an antimycobacterial circuit between dendritic and helper T cells in human SPPL2a deficiency. Nat Immunol 19:973-985
Casanova, Jean-Laurent; Abel, Laurent (2018) Human genetics of infectious diseases: Unique insights into immunological redundancy. Semin Immunol 36:1-12
Abel, Laurent; Fellay, Jacques; Haas, David W et al. (2018) Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives. Lancet Infect Dis 18:e64-e75
Ne, Karaca; G, Aksu; E, Ulusoy et al. (2016) Disseminated BCG Infectious Disease and Hyperferritinemia in a Patient With a Novel NEMO Mutation. J Investig Allergol Clin Immunol 26:268-271
El Azbaoui, S; Sabri, A; Ouraini, S et al. (2016) Utility of the QuantiFERON-TB Gold In-Tube assay for the diagnosis of tuberculosis in Moroccan children. Int J Tuberc Lung Dis 20:1639-1646
El Azbaoui, S; Alaoui Mrani, N; Sabri, A et al. (2015) Pott's disease in Moroccan children: clinical features and investigation of the interleukin-12/interferon-? pathway. Int J Tuberc Lung Dis 19:1455-62
Sharma, Varun K; Pai, Gautham; Deswarte, Caroline et al. (2015) Disseminated Mycobacterium avium complex infection in a child with partial dominant interferon gamma receptor 1 deficiency in India. J Clin Immunol 35:459-62
Olbrich, Peter; Martínez-Saavedra, Maria Teresa; Perez-Hurtado, José Maria et al. (2015) Diagnostic and therapeutic challenges in a child with complete interferon-? receptor 1 deficiency. Pediatr Blood Cancer 62:2036-9

Showing the most recent 10 out of 42 publications